Abstract
3-phosphoinositide dependent kinase-1 (PDK1) has been shown to be a critical regulator of the PI3K-Akt pathway. PDK1 can activate Akt and participates in the activation of PI3K-Akt signaling pathway to promote tumor development, invasion and metastasis. At present, it has been found that PDK1 is highly expressed in head and neck cancer, multiple myeloma, pancreatic cancer, esophageal cancer, colon cancer and other malignant tumors. Thereby inhibiting PDK1 overexpression may provide a new breakthrough for the treatment of malignant tumor. At present, many kinds of PDK1 inhibitors have been put into production, which plays an important role in tumor therapy. Key words: Neoplasms; Signal transduction; 3-Phosphoinositide dependent kinase-1
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
